Welcome to the ADVANZ® PHARMA Antimicrobial Voluntary Evaluation Program(ADVANZ® PHARMA AVEP)
coordinated by
Questions? Please contact International Health Management Associates (IHMA Europe Sàrl) +41 (0)24 473 75 10 advanzpharma@ihma.com
All the information and personal data you share with us will be protected and kept confidential in line with our company policy on data protection accessible here https://www.advanzpharma.com/privacy-policy. By clicking on the button “Register for Enrollment” or contacting us by phone or at the advanzpharma@ihma.com address and submitting your personal information as requested in particular in the concerned form you consent to the processing of your personal data in accordance with our privacy policy. The collected information will be used only for the management of your request and will be stored for a limited period, proportionate to the aims pursued. You have a right of access to the personal data which we may hold about you as well as various other rights as outlined in our privacy policy. To exercise any of those rights, or if you have any comments or questions about our privacy policy, you can address your request to the following email address: enquiries@advanzpharma.com.
Register for Enrollment
Ceftobiprole is an advanced-generation cephalosporin with rapid bactericidal activity against Gram-positive and Gram-negative bacteria including MRSA, MSSA, CoNS, Enterococcus faecalis, and Pseudomonas ssp. Ceftobiprole is indicated in Hospital-acquired pneumonia (HAP) excluding ventilator-associated pneumonia (VAP) and Community-acquired pneumonia (CAP). Ceftobiprole is administered intravenously and is the active moity of the prodrug ceftobiprole medocaril.
Dalbavancin is the first single-dose, 30-min IV antibiotic for ABSSSI (acute bacterial skin and skin structure infections) providing a full course of treatment. Dalbavancin is a lipoglycopeptide with bactericidal activity against relevant Gram-positive pathogens for ABSSSI including MRSA, MSSA, and CoNS.
Cefepime/Enmetazobactam is a novel and targeted Beta lactam/ Beta lactamase inhibitor combination indicated for the treatment of complicated urinary tract infections, nosocomial pneumonia and bacteremia caused by gram-negative bacteria. Enmetazobactam restored cefepime activity against ESBL-positive isolates and greatly enhanced the activity of cefepime against isolates encoding AmpC, AmpC + ESBL and ESBL + OXA genes. Cefepime/Enmetzobacatm (2g/0.5g) is administered intravenously every 8 hours.
Please confirm you are a Healthcare Professional.
© 2025
For research use only. Not for use in diagnostic procedures.
Accept Privacy Statement